Xenon Pharmaceuticals (XENE)Deerfield Management Company, L.P. added to its stake +1.07M shares

1.62M

Shares reported · +1.07M vs prior quarter

1.3%

Disclosed portfolio weight

$94M

Reported value

Holdings as of

Mar 31, 2026

Filed

May 15, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Apr 7, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 7, 2026, Xenon Pharmaceuticals Inc. (the “Company”) amended and restated the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan (as amended and restated, the “2025 Inducement Plan”) to increase the maximum number of shares of its common stock reserved for issuance under the 2025 Inducement Plan from 900,000 shares to 1,175,000 shares (subject to adjustments as provided in the 2025…”
2. May 7, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors

What came next

1. Jun 2, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“As discussed in Item 5.07 below, upon the recommendation of the Board of Directors (the “Board”) of Xenon Pharmaceuticals Inc. (the “Company"), the shareholders of the Company, at the Company's annual meeting of shareholders held on June 2, 2026 (the “Annual Meeting”), approved the Xenon Pharmaceuticals Inc. 2026 Equity Incentive Plan (the “2026 Plan”), to replace the Amended and Restated Xenon Pharmaceuticals Inc.…”
2. Aug 6, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Xenon Pharmaceuticals

For Xenon Pharmaceuticals, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 4 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its XENE page.

How this filing works

• SEC Form 13F

Other disclosures at Xenon Pharmaceuticals

• SEC Form 4Oct 1, 2026
• SEC Form 4Oct 1, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 12, 2026

Everything OQRO holds on this company is on its XENE page.